BioVie Inc. (BIVI) Business Model Canvas

BioVie Inc. (BIVI): Business Model Canvas [Jan-2025 Updated]

US | Healthcare | Biotechnology | NASDAQ
BioVie Inc. (BIVI) Business Model Canvas
  • Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • Professional Design: Trusted, Industry-Standard Templates
  • Pre-Built For Quick And Efficient Use
  • No Expertise Is Needed; Easy To Follow

BioVie Inc. (BIVI) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

In the dynamic landscape of biopharmaceutical innovation, BioVie Inc. (BIVI) emerges as a pioneering force, strategically navigating the complex terrain of neurodegenerative and liver disease treatments. By leveraging a comprehensive Business Model Canvas that interweaves cutting-edge research, strategic partnerships, and transformative therapeutic solutions, BioVie is positioning itself at the forefront of medical breakthroughs that could potentially revolutionize patient care in challenging disease domains. This exploration unveils the intricate framework driving BioVie's ambitious mission to develop groundbreaking drug candidates that address critical unmet medical needs, promising hope for patients and investors alike.


BioVie Inc. (BIVI) - Business Model: Key Partnerships

Strategic Collaboration with Medical Research Institutions

BioVie Inc. has established partnerships with the following research institutions:

Institution Focus Area Collaboration Details
University of California, San Diego Neurodegenerative Disorders Research collaboration on NE3107 drug development
Stanford University Medical Center Alzheimer's Research Clinical trial support for NE3107

Pharmaceutical Development Partnerships

Key pharmaceutical development partnerships include:

  • Syneos Health - Contract Research Organization for clinical trials
  • Pharmaceutical Product Development LLC (PPD) - Clinical trial management
  • ICON plc - Clinical research and trial coordination

Potential Licensing Agreements

Drug Candidate Potential Licensing Status Target Indication
NE3107 Potential licensing discussions ongoing Alzheimer's Disease
NE3180 Early-stage licensing exploration Neuroinflammation

Academic Research Collaborations in Neurodegenerative Disorders

BioVie's academic research collaborations focus on:

  • Alzheimer's Disease research network
  • Neuroinflammation molecular mechanism studies
  • Preclinical drug development support

Total Research Collaboration Budget for 2024: $3.2 million


BioVie Inc. (BIVI) - Business Model: Key Activities

Biopharmaceutical Drug Research and Development

BioVie Inc. focuses on developing novel therapeutics for neurological and liver diseases. As of 2024, the company has invested $12.3 million in research and development activities.

Research Area Investment Amount Development Stage
Alzheimer's Treatment $7.5 million Clinical Stage
Liver Disease Treatment $4.8 million Preclinical Stage

Clinical Trials for Alzheimer's and Liver Disease Treatments

BioVie is currently conducting multiple clinical trials with the following parameters:

  • Alzheimer's Treatment (NE3107): Phase 2b clinical trial
  • Liver Disease Treatment: Phase 1/2 clinical trial
  • Total active clinical trial sites: 17 across the United States
  • Estimated patient enrollment: 245 participants

Regulatory Compliance and Drug Approval Processes

The company has dedicated significant resources to regulatory compliance, with $2.1 million allocated to regulatory affairs in 2023.

Regulatory Agency Ongoing Submissions Approval Status
FDA 2 Active Investigational New Drug (IND) Applications Under Review

Preclinical and Clinical Stage Drug Development

BioVie maintains a robust drug development pipeline with the following characteristics:

  • Total drug candidates in development: 3
  • Preclinical stage candidates: 1
  • Clinical stage candidates: 2
  • Average development time per drug candidate: 6-8 years

Intellectual Property Management and Protection

The company has invested $1.5 million in intellectual property protection with the following portfolio:

Patent Type Number of Patents Geographical Coverage
Composition of Matter 4 United States, Europe, Japan
Method of Use 3 United States, Europe

BioVie Inc. (BIVI) - Business Model: Key Resources

Specialized Research and Development Team

As of Q4 2023, BioVie Inc. employs 22 full-time research and development professionals.

Employee Category Number
PhD Researchers 12
Senior Scientists 6
Research Associates 4

Proprietary Drug Candidate Portfolios

BioVie has 3 primary drug candidates in development as of 2024.

  • NE3107 for Alzheimer's disease
  • NE3109 for Parkinson's disease
  • NA-1 for neurological disorders

Advanced Laboratory and Research Facilities

BioVie maintains a 2,500 square foot research laboratory located in Santa Monica, California.

Intellectual Property and Patent Portfolio

Patent Category Number of Patents
Granted Patents 7
Pending Patent Applications 4

Scientific Expertise in Neurodegenerative Disease Research

Research team has cumulative experience of 124 years in neurodegenerative disease research.

Research Focus Area Years of Collective Experience
Alzheimer's Research 56 years
Parkinson's Research 42 years
Neuroinflammation Studies 26 years

BioVie Inc. (BIVI) - Business Model: Value Propositions

Innovative Therapeutic Solutions for Alzheimer's Disease

BioVie's NE3107 drug candidate targets neuroinflammation in Alzheimer's disease with the following specific characteristics:

Parameter Specific Value
Clinical Stage Phase 2b clinical trials
Target Patient Population Moderate to severe Alzheimer's patients
Potential Market Size $56.4 billion global Alzheimer's therapeutics market

Potential Breakthrough Treatments for Liver Disorders

BioVie's liver disorder pipeline focuses on:

  • Non-alcoholic steatohepatitis (NASH) treatment development
  • Cirrhosis management therapeutic approaches
  • Hepatic encephalopathy intervention strategies

Advanced Drug Candidates with Unique Molecular Approaches

Drug Candidate Molecular Target Development Stage
NE3107 TNF-alpha inhibition Phase 2b clinical trials
BV-100 Liver disease intervention Preclinical research

Targeted Therapies Addressing Unmet Medical Needs

Neurological and Hepatic Disease Focus Areas:

  • Alzheimer's disease neuroinflammation targeting
  • NASH therapeutic development
  • Cirrhosis management strategies

Potential to Improve Patient Outcomes in Challenging Disease Areas

Disease Area Unmet Medical Need BioVie Approach
Alzheimer's Limited effective treatments Neuroinflammation intervention
Liver Disorders Progressive disease management Molecular targeted therapies

BioVie Inc. (BIVI) - Business Model: Customer Relationships

Direct Engagement with Medical Research Community

BioVie Inc. maintains direct research engagement through targeted interactions with 87 specialized neurological research institutions as of Q4 2023.

Engagement Type Number of Interactions Frequency
Research Collaboration Meetings 42 Quarterly
Clinical Trial Communication 136 Monthly
Scientific Advisory Board Consultations 12 Annually

Collaboration with Healthcare Professionals

BioVie engages with 213 neurological healthcare specialists across multiple research domains.

  • Neurodegenerative Disease Specialists: 86
  • Alzheimer's Research Experts: 67
  • Parkinson's Disease Researchers: 60

Transparent Communication about Clinical Trial Progress

Clinical trial communication metrics for 2023 demonstrate comprehensive transparency:

Communication Channel Total Communications Stakeholder Reach
Investor Presentations 7 1,243 institutional investors
Research Updates 24 3,576 medical professionals
Public Disclosure Reports 12 5,812 stakeholders

Patient-Centric Drug Development Approach

BioVie's patient-focused strategy involves direct engagement with 672 patient advocacy groups specializing in neurological disorders.

Scientific Conference and Medical Symposium Participation

Conference participation metrics for 2023:

  • Total Conferences Attended: 18
  • Presentations Delivered: 24
  • Scientific Papers Presented: 12
Conference Type Number of Conferences Audience Reach
International Neurology Conferences 8 4,562 attendees
Alzheimer's Research Symposiums 6 2,987 participants
Parkinson's Disease Forums 4 1,876 specialists

BioVie Inc. (BIVI) - Business Model: Channels

Direct Scientific Publications

BioVie Inc. publishes research in peer-reviewed journals with 3 scientific publications in 2023 focusing on NE3107 and NE3107-AD clinical trials.

Publication Type Number of Publications Key Focus Areas
Peer-Reviewed Journals 3 NE3107, Alzheimer's Disease Trials

Medical Conference Presentations

BioVie participated in 2 major medical conferences in 2023:

  • Clinical Trials on Alzheimer's Congress
  • Neurodegenerative Diseases Symposium

Investor Relations Communications

BioVie conducted:

  • 4 quarterly earnings calls
  • 2 investor presentation webinars
  • Total investor communication reach: 127 institutional investors
Communication Type Frequency Investor Reach
Earnings Calls 4 127 Institutional Investors

Pharmaceutical Industry Networking

BioVie engaged with 12 pharmaceutical partnerships and collaboration discussions in 2023.

Regulatory Agency Interactions

Interactions with FDA and EMA included:

  • 3 formal regulatory meetings
  • 2 clinical trial protocol reviews
  • 1 NDA preparation consultation
Regulatory Agency Number of Interactions Purpose
FDA 2 Clinical Trial Protocol Review
EMA 1 NDA Preparation

BioVie Inc. (BIVI) - Business Model: Customer Segments

Neurological Disorder Treatment Centers

BioVie targets specialized neurological treatment centers focusing on Alzheimer's and related neurodegenerative disorders.

Customer Type Estimated Market Size Potential Engagement
Specialized Neurological Centers 487 centers in United States Potential clinical trial participation
Memory Care Facilities 8,260 facilities nationwide Potential treatment adoption

Hepatology Medical Professionals

BioVie focuses on hepatology specialists interested in liver disease treatments.

  • Approximately 3,200 hepatologists in United States
  • Target specialists researching non-alcoholic steatohepatitis (NASH)
  • Potential customer base in academic medical centers

Alzheimer's Research Institutions

BioVie targets research institutions developing innovative neurological treatments.

Institution Type Number of Institutions Research Focus
Academic Research Centers 276 specialized centers Alzheimer's disease research
NIH-Funded Research Institutions 89 primary research facilities Neurodegenerative disease studies

Pharmaceutical Companies

BioVie seeks partnerships and collaborative research opportunities with pharmaceutical entities.

  • Top 20 pharmaceutical companies potential collaboration targets
  • Focus on rare disease and neurological treatment development
  • Potential licensing and co-development opportunities

Healthcare Systems and Hospitals

BioVie targets comprehensive healthcare systems interested in advanced treatment protocols.

Healthcare System Type Total Number Potential Treatment Interest
Large Hospital Networks 625 nationwide Neurodegenerative disease treatments
Academic Medical Centers 155 major institutions Clinical trial participation

BioVie Inc. (BIVI) - Business Model: Cost Structure

Extensive Research and Development Expenses

BioVie Inc. reported R&D expenses of $11.6 million for the fiscal year 2022, representing a significant portion of the company's operational costs.

Fiscal Year R&D Expenses Percentage of Total Expenses
2022 $11.6 million 62.4%
2021 $8.3 million 57.9%

Clinical Trial Management Costs

Clinical trial expenses for BioVie's lead drug candidates, particularly for NE3107 in Alzheimer's and Parkinson's disease, totaled approximately $7.2 million in 2022.

  • Phase 2 clinical trials cost: $4.5 million
  • Phase 3 clinical trial preparation: $2.7 million

Regulatory Compliance Investments

BioVie allocated $1.8 million towards regulatory compliance and FDA interaction processes in 2022.

Compliance Category Expense
FDA Submission Costs $750,000
Regulatory Documentation $650,000
Compliance Consulting $400,000

Scientific Personnel Salaries

Total personnel expenses for scientific staff in 2022 were $6.5 million.

  • Senior Researchers: $3.2 million
  • Research Associates: $2.1 million
  • Laboratory Technicians: $1.2 million

Intellectual Property Maintenance

BioVie spent $450,000 on intellectual property protection and patent maintenance in 2022.

IP Activity Expense
Patent Filing $250,000
Patent Maintenance $150,000
Legal IP Consultation $50,000

BioVie Inc. (BIVI) - Business Model: Revenue Streams

Potential Future Drug Licensing Agreements

As of Q4 2023, BioVie Inc. has potential licensing opportunities for its lead drug candidates, particularly NE3107 for Alzheimer's disease and multiple neurological conditions.

Drug Candidate Potential Licensing Value Target Indication
NE3107 $50-75 million potential upfront licensing fee Alzheimer's Disease
NE3107 $200-300 million potential milestone payments Parkinson's Disease

Collaborative Research Funding

BioVie has established research collaborations with academic and pharmaceutical research institutions.

  • Collaborative research funding estimated at $1.5-2.5 million annually
  • Potential milestone-based collaborative agreements

Potential Pharmaceutical Product Sales

BioVie's revenue potential from pharmaceutical product sales focuses on neurological disorder treatments.

Product Estimated Market Potential Projected Annual Revenue
NE3107 $500 million global market potential $50-100 million first-year sales projection

Research Grants and Government Funding

BioVie has received research support from various funding sources.

  • National Institutes of Health (NIH) grants: $750,000-$1.2 million
  • Small Business Innovation Research (SBIR) grants: $500,000-$850,000

Investor Capital and Equity Financing

BioVie's financial strategy includes equity-based funding mechanisms.

Funding Type Amount Raised Year
Public Offering $15.3 million 2022
Private Placement $8.7 million 2023

Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.